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Effects of Endogenous and Human 4R
to 3R Tau Splicing
Smruti Rath
Mentors: Timothy Miller and Kathleen Schoch
Tau protein deposition has been implicated in the progression of several diseases
collectively referred to as Tauopathies. This study investigated the effects of reducing 4R
Tau in vivo to understand the mechanisms by which Tau neurofibrillary tangles affect
the progression of disease. In order to do so, antisense oligonucleotides (ASOs) were
utilized for the purpose of 4R to 3R Tau splicing in mice expressing either mouse
(mTau) or human tau (hTau). These ASOs are short nucleotide sequences that were
designed with a modified backbone to bind to Tau mRNA and alter its splicing.
Three cohorts of hTau mice were tested for decreased disease pathology. Treatment
groups were saline, scrambled oligonucleotide, and 4R to 3R splicing oligonucleotide.
Mice received the drug for 28 days (25 µg/day) via an osmotic pump to the right lateral
ventricle. Following drug treatment, mice were injected with PTZ (Pentylenetetrazole)
to induce seizures which were observed and scored. The mice were then euthanized for
brain tissue collection and Tau protein levels were measured by quantitative real-time
PCR. A cohort of mTau mice was also treated to observe location of Fyn and Tau protein
isoforms in the synaptosome using Western Blot techniques.
The splicing oligonucleotides successfully reduced 4R Tau levels, and the scrambled
oligonucleotide from the second cohort of hTau mice maintained similar levels of Total
Tau. Current results indicate that 4R to 3R splicing in hTau mice did not significantly
reduce Tau pathology. Results also did not indicate a significant decrease in Fyn protein
levels in the Synaptosome following splicing treatment. Future directions include using
more cohorts of hTau mice to test for decreased seizure pathology with 4R to 3R
splicing. Co-immunoprecipitation will also be carried out to determine binding of Fyn
to 4R and 3R Tau in the Synaptosome of mTau mice.
